Patient Recruitment Services

Patient enrollment is often the largest single cause of delays in clinical development and can consume up to one-quarter of the entire clinical development timeline. CMX has been a pioneer in patient recruitment and retention services since 1995.

Patient Recruitment Services expedites patient enrollment at each individual investigational site by effective central advertising and call centre referral service.


CMX will customize its advertising approach to suit the requirements of the client and the target patient population. We provide subject enrollment support for large, multicentre early and late phase trials in both official languages. Our service is PIPEDA compliant and we have an efficient IRB approval process for advertising. Our call center team is professional and honest enabling them to quickly earn the trust of potential study candidates.


CMX offers central advertisement management in printed media, radio and on the internet. Our strong relationship with large media networks give us a cost advantage which is passed to our clients.

Our leading edge call centre technology and dedicated toll-free lines ensure that queries from potential study candidates are addressed in an efficient manner.

CMX also offers advertisement design services and pre-qualifying script writing. These services will provide your study with effective advertising that targets your study population. In addition, CMX handles all ethics review board script and advertising submissions. Our clients are provided with patient referral tracking, randomization metrics and trends reporting to indicate the advertising effectiveness.


CMX has a proven track record for providing a high return on advertising investments. Our professional call center staff, creative advertising and strategic placement of ads act in a synergistic fashion to ultimately provide accelerated enrollment of pre-qualified, motivated eligible study patients, reduce screening failures and have shown to improve enrollment for underperforming trials.